Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

RAIN ONCOLOGY INC.

(RAIN)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-30 pm EST
9.680 USD   -3.39%
01/23Rain Oncology Inc. : Regulation FD Disclosure (form 8-K)
AQ
01/23Phase 1 Clinical Data of Milademetan Published in Journal of Clinical Oncology
AQ
01/23Rain Oncology Inc. Announces Phase 1 Clinical Data of Milademetan Publishes in Journal of Clinical Oncology
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

HC Wainwright Initiates Rain Therapeutics at Buy With $10 Price Target

09/12/2022 | 06:58am EST


ę MT Newswires 2022
All news about RAIN ONCOLOGY INC.
01/23Rain Oncology Inc. : Regulation FD Disclosure (form 8-K)
AQ
01/23Phase 1 Clinical Data of Milademetan Published in Journal of Clinical Oncology
AQ
01/23Rain Oncology Inc. Announces Phase 1 Clinical Data of Milademetan Publishes in Journal ..
CI
01/23Mizuho Starts Rain Oncology at Buy With $18 Price Target
MT
01/23Rain Oncology's Likely 'Positive Outcome' in Phase 3 Milademetan Study in Q1 Underpinni..
MT
01/11Transcript : Rain Therapeutics Inc. Presents at 41st Annual J.P. Morgan Healt..
CI
01/06Lifesci Capital Starts Rain Therapeutics at Outperform With $17 Price Target
MT
01/05EF Hutton Initiates Rain Therapeutics at Buy With $16 Price Target
MT
2022Rain Therapeutics Inc. will Change its Name to Rain Oncology Inc
CI
2022Rain Therapeutics Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, ..
AQ
More news
Analyst Recommendations on RAIN ONCOLOGY INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -70,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,03x
Yield 2022 -
Capitalization 340 M 340 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 44
Free-Float 56,1%
Chart RAIN ONCOLOGY INC.
Duration : Period :
Rain Oncology Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RAIN ONCOLOGY INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 9,68 $
Average target price 18,11 $
Spread / Average Target 87,1%
EPS Revisions
Managers and Directors
Avanish Vellanki Chairman & Chief Executive Officer
Robert Doebele President & Chief Scientific Officer
Nelson D. Cabatuan Senior Vice President-Finance & Administration
Lucio Tozzi Senior Vice President-Clinical Operations
Richard Paul Bryce Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
RAIN ONCOLOGY INC.21.00%340
MODERNA, INC.5.42%72 745
LONZA GROUP AG17.24%42 787
IQVIA HOLDINGS INC.12.00%42 622
ALNYLAM PHARMACEUTICALS, INC.-2.64%28 465
SEAGEN INC.8.93%26 117